Drug intelligence / Profile preview

JB-131

Development stage: Preclinical
Lead developer: Junten Bio

Overview

JB-131 is an investigational drug candidate currently in the preclinical stage of development by Junten Bio. It is being developed for applications in organ transplantation, likely aimed at inducing immune tolerance to prevent graft rejection. While Junten Bio's lead programs (such as JB-101) utilize induced suppressor T-cell (isTreg) technology, the specific modality and molecular target of JB-131 have not been publicly disclosed. The program is part of the company's broader effort to develop therapies that reduce or eliminate the need for lifelong immunosuppression in transplant recipients.

Beyond the preview

Go deeper on JB-131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JB-131.

Explore the full profile